Afshari AR, Motamed-Sanaye A, Sabri H, et al., 2021. Neurokinin-1 receptor (NK-1R) antagonists: potential targets in the treatment of glioblastoma multiforme. Curr Med Chem, 28(24):4877-4892. https://doi.org/10.2174/0929867328666210113165805https://doi.org/10.2174/0929867328666210113165805

Agelopoulos K, Rülander F, Dangelmaier J, et al., 2019. Neurokinin 1 receptor antagonists exhibit peripheral effects in prurigo nodularis including reduced ERK1/2 activation. J Eur Acad Dermatol Venereol, 33(12):2371-2379. https://doi.org/10.1111/jdv.15905https://doi.org/10.1111/jdv.15905

Alwazzan A, Mehboob R, Hassan A, et al., 2020. Elevated neurokinin-1 receptor expression in uterine products of conception is associated with first trimester miscarriages. Front Physiol, 11:554766. https://doi.org/10.3389/fphys.2020.554766https://doi.org/10.3389/fphys.2020.554766

Bai TR, Zhou D, Weir T, et al., 1995. Substance P (NK1)- and neurokinin A (NK2)-receptor gene expression in inflammatory airway diseases. Am J Physiol, 269(3 Pt 1):L309-L317. https://doi.org/10.1152/ajplung.1995.269.3.L309https://doi.org/10.1152/ajplung.1995.269.3.L309

Bakirtzi K, Law IKM, Fang K, et al., 2019. MiR-21 in substance P-induced exosomes promotes cell proliferation and migration in human colonic epithelial cells. Am J Physiol, 317(6):G802-G810. https://doi.org/10.1152/ajpgi.00043.2019https://doi.org/10.1152/ajpgi.00043.2019

Barbe MF, Hilliard BA, Fisher PW, et al., 2020. Blocking substance P signaling reduces musculotendinous and dermal fibrosis and sensorimotor declines in a rat model of overuse injury. Connect Tissue Res, 61(6):604-619. https://doi.org/10.1080/03008207.2019.1653289https://doi.org/10.1080/03008207.2019.1653289

Beirith I, Renz BW, Mudusetti S, et al., 2021. Identification of the neurokinin-1 receptor as targetable stratification factor for drug repurposing in pancreatic cancer. Cancers (Basel), 13(11):2703. https://doi.org/10.3390/cancers13112703https://doi.org/10.3390/cancers13112703

Biadsee A, Biadsee A, Kassem F, et al., 2020. Olfactory and oral manifestations of COVID-19: sex-related symptoms—a potential pathway to early diagnosis. Otolaryngol Head Neck Surg, 163(4):722-728. https://doi.org/10.1177/0194599820934380https://doi.org/10.1177/0194599820934380

Bubak AN, Como CN, Blackmon AM, et al., 2018. Varicella zoster virus induces nuclear translocation of the neurokinin-1 receptor, promoting lamellipodia formation and viral spread in spinal astrocytes. J Infect Dis, 218(8):1324-1335. https://doi.org/10.1093/infdis/jiy297https://doi.org/10.1093/infdis/jiy297

Chen Y, Chauhan SK, Lee HS, et al., 2014. Chronic dry eye disease is principally mediated by effector memory TH17 cells. Mucosal Immunol, 7(1):38-45. https://doi.org/10.1038/mi.2013.20https://doi.org/10.1038/mi.2013.20

Chu HW, Kraft M, Krause JE, et al., 2000. Substance P and its receptor neurokinin 1 expression in asthmatic airways. J Allergy Clin Immunol, 106(4):713-722. https://doi.org/10.1067/mai.2000.109829https://doi.org/10.1067/mai.2000.109829

Craig VJ, Zhang L, Hagood JS, et al., 2015. Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol, 53(5):585-600. https://doi.org/10.1165/rcmb.2015-0020TRhttps://doi.org/10.1165/rcmb.2015-0020TR

de Felipe C, Herrero JF, O'Brien JA, et al., 1998. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature, 392(6674):394-397. https://doi.org/10.1038/32904https://doi.org/10.1038/32904

Definition and Classification Subcommittee, 2007. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf, 5(2):75-92. https://doi.org/10.1016/s1542-0124(12)70081-2https://doi.org/10.1016/s1542-0124(12)70081-2

Dehlin HM, Levick SP, 2014. Substance P in heart failure: the good and the bad. Int J Cardiol, 170(3):270-277. https://doi.org/10.1016/j.ijcard.2013.11.010https://doi.org/10.1016/j.ijcard.2013.11.010

Deng XT, Tang SM, Wu PY, et al., 2019. SP/NK-1R promotes gallbladder cancer cell proliferation and migration. J Cell Mol Med, 23(12):7961-7973. https://doi.org/10.1111/jcmm.14230https://doi.org/10.1111/jcmm.14230

Dong JQ, Feng F, Xu GH, et al., 2015. Elevated SP/NK-1R in esophageal carcinoma promotes esophageal carcinoma cell proliferation and migration. Gene, 560(2):205-210. https://doi.org/10.1016/j.gene.2015.02.002https://doi.org/10.1016/j.gene.2015.02.002

Dong YY, Mo X, Hu YB, et al., 2020. Epidemiology of COVID-19 among children in China. Pediatrics, 145(6):e20200702. https://doi.org/10.1542/peds.2020-0702https://doi.org/10.1542/peds.2020-0702

Douglas SD, Leeman SE, 2011. Neurokinin-1 receptor: functional significance in the immune system in reference to selected infections and inflammation. Ann N Y Acad Sci, 1217:83-95. https://doi.org/10.1111/j.1749-6632.2010.05826.xhttps://doi.org/10.1111/j.1749-6632.2010.05826.x

Ebrahimi S, Javid H, Alaei A, et al., 2020. New insight into the role of substance P/neurokinin-1 receptor system in breast cancer progression and its crosstalk with microRNAs. Clin Genet, 98(4):322-330. https://doi.org/10.1111/cge.13750https://doi.org/10.1111/cge.13750

Ebrahimi S, Mirzavi F, Aghaee-Bakhtiari SH, et al., 2022. SP/NK1R system regulates carcinogenesis in prostate cancer: shedding light on the antitumoral function of aprepitant. Biochim Biophys Acta Mol Cell Res, 1869(5):119221. https://doi.org/10.1016/j.bbamcr.2022.119221https://doi.org/10.1016/j.bbamcr.2022.119221

Foulsham W, Marmalidou A, Amouzegar A, et al., 2017. Review: the function of regulatory T cells at the ocular surface. Ocul Surf, 15(4):652-659. https://doi.org/10.1016/j.jtos.2017.05.013https://doi.org/10.1016/j.jtos.2017.05.013

García-Aranda M, Téllez T, McKenna L, et al., 2022. Neurokinin-1 receptor (NK-1R) antagonists as a new strategy to overcome cancer resistance. Cancers (Basel), 14(9):2255. https://doi.org/10.3390/cancers14092255https://doi.org/10.3390/cancers14092255

Ge CT, Huang HM, Huang FY, et al., 2019. Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload. Proc Natl Acad Sci USA, 116(39):19635-19645. https://doi.org/10.1073/pnas.1908998116https://doi.org/10.1073/pnas.1908998116

Ghahremanloo A, Javid H, Afshari AR, et al., 2021. Investigation of the role of neurokinin-1 receptor inhibition using aprepitant in the apoptotic cell death through PI3K/Akt/NF-κB signal transduction pathways in colon cancer cells. Biomed Res Int, 2021:1383878. https://doi.org/10.1155/2021/1383878https://doi.org/10.1155/2021/1383878

Ghasemi A, Hashemy SI, Aghaei M, et al., 2018. Leptin induces matrix metalloproteinase 7 expression to promote ovarian cancer cell invasion by activating ERK and JNK pathways. J Cell Biochem, 119(2):2333-2344. https://doi.org/10.1002/jcb.26396https://doi.org/10.1002/jcb.26396

Ghasemi A, Saeidi J, Azimi-Nejad M, et al., 2019. Leptin-induced signaling pathways in cancer cell migration and invasion. Cell Oncol (Dordr), 42(3):243-260. https://doi.org/10.1007/s13402-019-00428-0https://doi.org/10.1007/s13402-019-00428-0

Gordon L, Polak JM, Moscoso GJ, et al., 1993. Development of the peptidergic innervation of human heart. J Anat, 183(Pt 1):131-140.

Halik PK, Lipiński PFJ, Matalińska J, et al., 2020. Radiochemical synthesis and evaluation of novel radioconjugates of neurokinin 1 receptor antagonist aprepitant dedicated for NK1R-positive tumors. Molecules, 25(16):3756. https://doi.org/10.3390/molecules25163756https://doi.org/10.3390/molecules25163756

Halik PK, Koźmiński P, Matalińska J, et al., 2022. In vitro biological evaluation of aprepitant based 177Lu-radioconjugates. Pharmaceutics, 14(3):607. https://doi.org/10.3390/pharmaceutics14030607https://doi.org/10.3390/pharmaceutics14030607

Isorna I, Esteban F, Solanellas J, et al., 2020. The substance P and neurokinin-1 receptor system in human thyroid cancer: an immunohistochemical study. Eur J Histochem, 64(2):3117. https://doi.org/10.4081/ejh.2020.3117https://doi.org/10.4081/ejh.2020.3117

Jin P, Qi DQ, Cui YH, et al., 2022. Aprepitant attenuates NLRC4-dependent neuronal pyroptosis via NK1R/PKCδ pathway in a mouse model of intracerebral hemorrhage. J Neuroinflammation, 19:198. https://doi.org/10.1186/s12974-022-02558-zhttps://doi.org/10.1186/s12974-022-02558-z

Kakade P, Pathan Z, Gite S, et al., 2022. Nanoparticle engineering of aprepitant using Nano-by-Design (NbD) approach. AAPS PharmSciTech, 23(6):204. https://doi.org/10.1208/s12249-022-02350-5https://doi.org/10.1208/s12249-022-02350-5

Kast RE, Ramiro S, Lladó S, et al., 2016. Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells. J Neurooncol, 126(3):425-431. https://doi.org/10.1007/s11060-015-1996-6https://doi.org/10.1007/s11060-015-1996-6

Khom S, Steinkellner T, Hnasko TS, et al., 2020. Alcohol dependence potentiates substance P/neurokinin-1 receptor signaling in the rat central nucleus of amygdala. Sci Adv, 6(12):eaaz1050. https://doi.org/10.1126/sciadv.aaz1050https://doi.org/10.1126/sciadv.aaz1050

Khorasani S, Boroumand N, Lavi Arab F, et al., 2020. The immunomodulatory effects of tachykinins and their receptors. J Cell Biochem, 121(5-6):3031-3041. https://doi.org/10.1002/jcb.29668https://doi.org/10.1002/jcb.29668

Kim RY, Sunkara KP, Bracke KR, et al., 2021. A microRNA-21-mediated SATB1/S100A9/NF-‍κB axis promotes chronic obstructive pulmonary disease pathogenesis. Sci Transl Med, 13(621):eaav7223. https://doi.org/10.1126/scitranslmed.aav7223https://doi.org/10.1126/scitranslmed.aav7223

Kitchens CA, McDonald PR, Pollack IF, et al., 2009. Synergy between microtubule destabilizing agents and neurokinin 1 receptor antagonists identified by an siRNA synthetic lethal screen. FASEB J, 23(S1):756.13-756.13. https://doi.org/10.1096/fasebj.23.1_supplement.756.13https://doi.org/10.1096/fasebj.23.1_supplement.756.13

Korfi F, Javid H, Assaran Darban R, et al., 2021. The effect of SP/NK1R on the expression and activity of catalase and superoxide dismutase in glioblastoma cancer cells. Biochem Res Int, 2021:6620708. https://doi.org/10.1155/2021/6620708https://doi.org/10.1155/2021/6620708

Kramer MS, Cutler N, Feighner J, et al., 1998. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science, 281(5383):1640-1645. https://doi.org/10.1126/science.281.5383.1640https://doi.org/10.1126/science.281.5383.1640

Kumar S, Gupta SK, 2013. Pharmaceutical solid dispersion technology: a strategy to improve dissolution of poorly water-soluble drugs. Recent Pat Drug Deliv Formul, 7(2):111-121. https://doi.org/10.2174/18722113113079990009https://doi.org/10.2174/18722113113079990009

Lee KS, Lee J, Kim HK, et al., 2021. Extracellular vesicles from adipose tissue-derived stem cells alleviate osteoporosis through osteoprotegerin and miR-21-5p. J Extracell Vesicles, 10(12):e12152. https://doi.org/10.1002/jev2.12152https://doi.org/10.1002/jev2.12152

Liu JW, Zou MJ, Piao HY, et al., 2015. Characterization and pharmacokinetic study of aprepitant solid dispersions with soluplus®. Molecules, 20(6):11345-11356. https://doi.org/10.3390/molecules200611345https://doi.org/10.3390/molecules200611345

Liu JW, Li SY, Ao W, et al., 2022a. Fabrication of an aprepitant nanosuspension using hydroxypropyl chitosan to increase the bioavailability. Biochem Biophys Res Commun, 631:72-77. https://doi.org/10.1016/j.bbrc.2022.09.031https://doi.org/10.1016/j.bbrc.2022.09.031

Liu JW, Li YJ, Ao W, et al., 2022b. Preparation and characterization of aprepitant solid dispersion with HPMCAS-LF. ACS Omega, 7(44):39907-39912. https://doi.org/10.1021/acsomega.2c04021https://doi.org/10.1021/acsomega.2c04021

Liu L, Burcher E, 2005. Tachykinin peptides and receptors: putting amphibians into perspective. Peptides, 26(8):1369-1382. https://doi.org/10.1016/j.peptides.2005.03.027https://doi.org/10.1016/j.peptides.2005.03.027

Liu XP, Zhu YL, Zheng W, et al., 2019. Antagonism of NK-1R using aprepitant suppresses inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes. Artif Cells Nanomed Biotechnol, 47(1):1628-1634. https://doi.org/10.1080/21691401.2019.1573177https://doi.org/10.1080/21691401.2019.1573177

Lorestani S, Ghahremanloo A, Jangjoo A, et al., 2020. Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in colorectal cancer. Mol Biol Rep, 47(5):3469-3474. https://doi.org/10.1007/s11033-020-05432-4https://doi.org/10.1007/s11033-020-05432-4

Maeda H, Wu J, Sawa T, et al., 2000. Tumor vascular permeability and the epr effect in macromolecular therapeutics: a review. J Control Release, 65(1-2):271-284. https://doi.org/10.1016/s0168-3659(99)00248-5https://doi.org/10.1016/s0168-3659(99)00248-5

Mahtal N, Lenoir O, Tinel C, et al., 2022. MicroRNAs in kidney injury and disease. Nat Rev Nephrol, 18(10):643-662. https://doi.org/10.1038/s41581-022-00608-6https://doi.org/10.1038/s41581-022-00608-6

Maroñas-Jiménez L, Estrach T, Gallardo F, et al., 2018. Aprepitant improves refractory pruritus in primary cutaneous T-cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas. Br J Dermatol, 178(4):e273-e274. https://doi.org/10.1111/bjd.16128https://doi.org/10.1111/bjd.16128

Martinez AN, Philipp MT, 2016. Substance P and antagonists of the neurokinin-1 receptor in neuroinflammation associated with infectious and neurodegenerative diseases of the central nervous system. J Neurol Neuromedicine, 1(2):29-36. https://doi.org/10.29245/2572.942x/2016/2.1020https://doi.org/10.29245/2572.942x/2016/2.1020

Mehboob R, Lavezzi AM, 2021. Neuropathological explan

ation of minimal COVID-19 infection rate in newborns, infants and children—a mystery so far. New insight into the role of substance P. J Neurol Sci, 420:117276. https://doi.org/10.1016/j.jns.2020.117276https://doi.org/10.1016/j.jns.2020.117276

Meléndez GC, Li JP, Law BA, et al., 2011. Substance P induces adverse myocardial remodelling via a mechanism involving cardiac mast cells. Cardiovasc Res, 92(3):420-429. https://doi.org/10.1093/cvr/cvr244https://doi.org/10.1093/cvr/cvr244

Miao YB, Quinn TP, 2021. Advances in receptor-targeted radiolabeled peptides for melanoma imaging and therapy. J Nucl Med, 62(3):313-318. https://doi.org/10.2967/jnumed.120.243840https://doi.org/10.2967/jnumed.120.243840

Mistrova E, Kruzliak P, Dvorakova MC, 2016. Role of substance P in the cardiovascular system. Neuropeptides, 58:41-51. https://doi.org/10.1016/j.npep.2015.12.005https://doi.org/10.1016/j.npep.2015.12.005

Mohamed MZ, Abed El Baky MF, Ali ME, et al., 2022. Aprepitant exerts anti-fibrotic effect via inhibition of TGF-β/Smad3 pathway in bleomycin-induced pulmonary fibrosis in rats. Environ Toxicol Pharmacol, 95:103940. https://doi.org/10.1016/j.etap.2022.103940https://doi.org/10.1016/j.etap.2022.103940

Mohammadi F, Javid H, Afshari AR, et al., 2020. Substance P accelerates the progression of human esophageal squamous cell carcinoma via MMP-2, MMP-9, VEGF-A, and VEGFR1 overexpression. Mol Biol Rep, 47(6):4263-4272. https://doi.org/10.1007/s11033-020-05532-1https://doi.org/10.1007/s11033-020-05532-1

Molinos-Quintana A, Trujillo-Hacha P, Piruat JI, et al., 2019. Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists. Invest New Drugs, 37:17-26. https://doi.org/10.1007/s10637-018-0607-8https://doi.org/10.1007/s10637-018-0607-8

Morgat C, Mishra AK, Varshney R, et al., 2014. Targeting neuropeptide receptors for cancer imaging and therapy: perspectives with bombesin, neurotensin, and neuropeptide-Y receptors. J Nucl Med, 55(10):1650-1657. https://doi.org/10.2967/jnumed.114.142000https://doi.org/10.2967/jnumed.114.142000

Mozafari M, Ebrahimi S, Darban RA, et al., 2022. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer. Mol Biol Rep, 49(2):1067-1076. https://doi.org/10.1007/s11033-021-06928-3https://doi.org/10.1007/s11033-021-06928-3

Muñoz M, Rosso M, 2010. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs, 28(2):187-193. https://doi.org/10.1007/s10637-009-9218-8https://doi.org/10.1007/s10637-009-9218-8

Muñoz M, Coveñas R, 2020a. The neurokinin-1 receptor antagonist aprepitant, a new drug for the treatment of hematological malignancies: focus on acute myeloid leukemia. J Clin Med, 9(6):1659. https://doi.org/10.3390/jcm9061659https://doi.org/10.3390/jcm9061659

Muñoz M, Coveñas R, 2020b. The neurokinin-1 receptor antagonist aprepitant: an intelligent bullet against cancer? Cancers, 12(9):2682. https://doi.org/10.3390/cancers12092682https://doi.org/10.3390/cancers12092682

Muñoz M, Rosso M, Robles-Frias MJ, et al., 2010. The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. Lab Invest, 90(8):‍1259-1269. https://doi.org/10.1038/labinvest.2010.92https://doi.org/10.1038/labinvest.2010.92

Muñoz M, González-Ortega A, Rosso M, et al., 2012. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists. Peptides, 38(2):318-325. https://doi.org/10.1016/j.peptides.2012.09.024https://doi.org/10.1016/j.peptides.2012.09.024

Muñoz M, González-Ortega A, Salinas-Martín MV, et al., 2014. The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer. Int J Oncol, 45(4):1658-1672. https://doi.org/10.3892/ijo.2014.2565https://doi.org/10.3892/ijo.2014.2565

Muñoz M, Covenas R, Esteban F, et al., 2015. The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs. J Biosci, 40(2):441-463. https://doi.org/10.1007/s12038-015-9530-8https://doi.org/10.1007/s12038-015-9530-8

Muñoz M, Crespo JC, Crespo JP, et al., 2019a. Neurokinin-1 receptor antagonist aprepitant and radiotherapy, a successful combination therapy in a patient with lung cancer: a case report. Mol Clin Oncol, 11(1):50-54. https://doi.org/10.3892/mco.2019.1857https://doi.org/10.3892/mco.2019.1857

Muñoz M, Rosso M, Coveñas R, 2019b. Neurokinin-1 receptor antagonists against hepatoblastoma. Cancers (Basel), 11(9):1258. https://doi.org/10.3390/cancers11091258https://doi.org/10.3390/cancers11091258

Muñoz M, Rosso M, Coveñas R, 2020. Triple negative breast cancer: how neurokinin-1 receptor antagonists could be used as a new therapeutic approach. Mini Rev Med Chem, 20(5):408-417. https://doi.org/10.2174/1389557519666191112152642https://doi.org/10.2174/1389557519666191112152642

Muñoz MF, Argüelles S, Rosso M, et al., 2022. The neurokinin-1 receptor is essential for the viability of human glioma cells: a possible target for treating glioblastoma. Biomed Res Int, 2022:6291504. https://doi.org/10.1155/2022/6291504https://doi.org/10.1155/2022/6291504

Mura S, Nicolas J, Couvreur P, 2013. Stimuli-responsive nanocarriers for drug delivery. Nat Mater, 12(11):991-1003. https://doi.org/10.1038/nmat3776https://doi.org/10.1038/nmat3776

Nizam E, Erin N, 2018. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; effects independent of substance P. Biomed Pharmacother, 108:263-270. https://doi.org/10.1016/j.biopha.2018.09.013https://doi.org/10.1016/j.biopha.2018.09.013

Noronha V, Bhattacharjee A, Patil VM, et al., 2020. Aprepitant for cough suppression in advanced lung cancer: a randomized trial. Chest, 157(6):1647-1655. https://doi.org/10.1016/j.chest.2019.11.048https://doi.org/10.1016/j.chest.2019.11.048

The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC Wkly, 2(8):113-122. https://doi.org/10.46234/ccdcw2020.032https://doi.org/10.46234/ccdcw2020.032

Olivieri F, Prattichizzo F, Giuliani A, et al., 2021. miR-21 and miR-146a: the micrornas of inflammaging and age-related diseases. Ageing Res Rev, 70:101374. https://doi.org/10.1016/j.arr.2021.101374https://doi.org/10.1016/j.arr.2021.101374

Olver I, Shelukar S, Thompson KC, 2007. Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant. Int J Nanomedicine, 2(1):13-18. https://doi.org/10.2147/nano.2007.2.1.13https://doi.org/10.2147/nano.2007.2.1.13

Quartara L, Altamura M, 2006. Tachykinin receptors antagonists: from research to clinic. Curr Drug Targets, 7(8):975-992. https://doi.org/10.2174/138945006778019381https://doi.org/10.2174/138945006778019381

Ramanujam D, Schön AP, Beck C, et al., 2021. MicroRNA-21-dependent macrophage-to-fibroblast signaling determines the cardiac response to pressure overload. Circulation, 143(15):1513-1525. https://doi.org/10.1161/circulationaha.120.050682https://doi.org/10.1161/circulationaha.120.050682

Ramírez-García PD, Retamal JS, Shenoy P, et al., 2019. A pH-responsive nanoparticle targets the neurokinin 1 receptor in endosomes to prevent chronic pain. Nat Nanotechnol, 14(12):1150-1159. https://doi.org/10.1038/s41565-019-0568-xhttps://doi.org/10.1038/s41565-019-0568-x

Ratti E, Bettica P, Alexander R, et al., 2013. Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies. J Psychopharmacol, 27(5):424-434. https://doi.org/10.1177/0269881113480990https://doi.org/10.1177/0269881113480990

Reinoso-Arija R, López-Ramírez C, Jimenez-Ruiz JA, et al., 2021. Effectiveness of aprepitant in post-acute COVID19 syndrome. Clin Case Rep, 9(9):e04646. https://doi.org/10.1002/ccr3.4646https://doi.org/10.1002/ccr3.4646

Ridhurkar DN, Ansari KA, Kumar D, et al., 2013. Inclusion complex of aprepitant with cyclodextrin: evaluation of physico-chemical and pharmacokinetic properties. Drug Dev Ind Pharm, 39(11):1783-1792. https://doi.org/10.3109/03639045.2012.737331https://doi.org/10.3109/03639045.2012.737331

Robinson P, Kasembeli M, Bharadwaj U, et al., 2016. Substance P receptor signaling mediates doxorubicin-induced cardiomyocyte apoptosis and triple-negative breast cancer chemoresistance. Biomed Res Int, 2016:1959270. https://doi.org/10.1155/2016/1959270https://doi.org/10.1155/2016/1959270

Roos C, Dahlgren D, Berg S, et al., 2017. In vivo mechanisms of intestinal drug absorption from aprepitant nanoformulations. Mol Pharm, 14(12):4233-4242. https://doi.org/10.1021/acs.molpharmaceut.7b00294https://doi.org/10.1021/acs.molpharmaceut.7b00294

Rouen PA, White ML, 2018. Dry eye disease: prevalence, assessment, and management. Home Healthc Now, 36(2):74-83. https://doi.org/10.1097/nhh.0000000000000652https://doi.org/10.1097/nhh.0000000000000652

Shi Y, Wang X, Meng Y, et al., 2021. A novel mechanism of endoplasmic reticulum stress- and c-Myc-degradation-mediated therapeutic benefits of antineurokinin-1 receptor drugs in colorectal cancer. Adv Sci (Weinh), 8(21):e2101936. https://doi.org/10.1002/advs.202101936https://doi.org/10.1002/advs.202101936

Schöppe J, Ehrenmann J, Klenk C, et al., 2019. Crystal structures of the human neurokinin 1 receptor in complex with clinically used antagonists. Nat Commun, 10:17. https://doi.org/10.1038/s41467-018-07939-8https://doi.org/10.1038/s41467-018-07939-8

Singh S, Kumaravel S, Dhole S, et al., 2021. Neuropeptide substance P enhances inflammation-mediated tumor signaling pathways and migration and proliferation of head and neck cancers. Indian J Surg Oncol, 12 (S1):93-102. https://doi.org/10.1007/s13193-020-01210-7https://doi.org/10.1007/s13193-020-01210-7

Smith JA, Harle A, Dockry R, et al., 2021. Aprepitant for cough in lung cancer. A randomized placebo-controlled trial and mechanistic insights. Am J Respir Crit Care Med, 203(6):737-745. https://doi.org/10.1164/rccm.202006-2359OChttps://doi.org/10.1164/rccm.202006-2359OC

Sosnik A, Seremeta KP, 2015. Advantages and challenges of the spray-drying technology for the production of pure drug particles and drug-loaded polymeric carriers. Adv Colloid Interface Sci, 223:40-54. https://doi.org/10.1016/j.cis.2015.05.003https://doi.org/10.1016/j.cis.2015.05.003

Steinhoff MS, von Mentzer B, Geppetti P, et al., 2014. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol Rev, 94(1):265-301. https://doi.org/10.1152/physrev.00031.2013https://doi.org/10.1152/physrev.00031.2013

Sugano K, Terada K, 2015. Rate- and extent-limiting factors of oral drug absorption: theory and applications. J Pharm Sci, 104(9):2777-2788. https://doi.org/10.1002/jps.24391https://doi.org/10.1002/jps.24391

Taketani Y, Dohlman T, Chen YH, et al., 2019. Restoration of regulatory T cell function in dry eye disease by targeting substance P/neurokinin 1 receptor. Invest Ophthalmol Vis Sci, 60(9):306. https://doi.org/10.1016/j.ajpath.2020.05.011https://doi.org/10.1016/j.ajpath.2020.05.011

Tang YJ, Liu JJ, Zhang DY, et al., 2020. Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol, 11:1708. https://doi.org/10.3389/fimmu.2020.01708https://doi.org/10.3389/fimmu.2020.01708

Tattersall FD, Rycroft W, Francis B, et al., 1996. Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology, 35(8):1121-1129. https://doi.org/10.1016/s0028-3908(96)00020-2https://doi.org/10.1016/s0028-3908(96)00020-2

Thom C, Ehrenmann J, Vacca S, et al., 2021. Structures of neurokinin 1 receptor in complex with Gq and Gs proteins reveal substance P binding mode and unique activation features. Sci Adv, 7(50):eabk2872. https://doi.org/10.1126/sciadv.abk2872https://doi.org/10.1126/sciadv.abk2872

Un H, Ugan RA, Kose D, et al., 2020. A novel effect of Aprepitant: protection for cisplatin-induced nephrotoxicity and hepatotoxicity. Eur J Pharmacol, 880:173168. https://doi.org/10.1016/j.ejphar.2020.173168https://doi.org/10.1016/j.ejphar.2020.173168

Wan PX, Su WR, Zhang YY, et al., 2020. LncRNA H19 initiates microglial pyroptosis and neuronal death in retinal ischemia/reperfusion injury. Cell Death Differ, 27:176-191. https://doi.org/10.1038/s41418-019-0351-4https://doi.org/10.1038/s41418-019-0351-4

Wang XL, He Y, Mackowiak B, et al., 2021. MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut, 70(4):784-795. https://doi.org/10.1136/gutjnl-2020-322526https://doi.org/10.1136/gutjnl-2020-322526

Widiapradja A, Manteufel EJ, Dehlin HM, et al., 2019. Regulation of cardiac mast cell maturation and function by the neurokinin-1 receptor in the fibrotic heart. Sci Rep, 9:11004. https://doi.org/10.1038/s41598-019-47369-0https://doi.org/10.1038/s41598-019-47369-0

Wu HZ, Cheng XE, Huang FY, et al., 2020. Aprepitant sensitizes acute myeloid leukemia cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Drug Des Devel Ther, 14:2413-2422. https://doi.org/10.2147/dddt.S244648https://doi.org/10.2147/dddt.S244648

Yamamoto H, 1993. Preserved endothelial function in the spastic segment of the human epicardial coronary artery in patients with variant angina—role of substance P in evaluating endothelial function. Eur Heart J, 14(Suppl I):118-122.

Yanai R, Nishida T, Hatano M, et al., 2020. Role of the neurokinin-1 receptor in the promotion of corneal epithelial wound healing by the peptides FGLM-NH2 and SSSR in neurotrophic keratopathy. Invest Ophthalmol Vis Sci, 61(8):29. https://doi.org/10.1167/iovs.61.8.29https://doi.org/10.1167/iovs.61.8.29

Yang Y, Zhou W, Xu XQ, et al., 2021. Aprepitant inhibits JNK and p38/MAPK to attenuate inflammation and suppresses inflammatory pain. Front Pharmacol, 12:811584. https://doi.org/10.3389/fphar.2021.811584https://doi.org/10.3389/fphar.2021.811584

Yeo S, An J, Park C, et al., 2020. Design and characterization of phosphatidylcholine-based solid dispersions of aprepitant for enhanced solubility and dissolution. Pharmaceutics, 12(5):407. https://doi.org/10.3390/pharmaceutics12050407https://doi.org/10.3390/pharmaceutics12050407

Zhang XW, Xing HJ, Zhao Y, et al., 2018. Pharmaceutical dispersion techniques for dissolution and bioavailability enhancement of poorly water-soluble drugs. Pharmaceutics, 10(3):74. https://doi.org/10.3390/pharmaceutics10030074https://doi.org/10.3390/pharmaceutics10030074

Zhang XW, Li L, Hu WQ, et al., 2022. Neurokinin-1 receptor promotes non-small cell lung cancer progression through transactivation of EGFR. Cell Death Dis, 13:41. https://doi.org/10.1038/s41419-021-04485-yhttps://doi.org/10.1038/s41419-021-04485-y

Zhao XN, Bai ZZ, Li CH, et al., 2020. The NK-1R antagonist aprepitant prevents LPS-induced oxidative stress and inflammation in RAW264.7 macrophages. Drug Des Devel Ther, 14:1943-1952. https://doi.org/10.2147/dddt.S244099https://doi.org/10.2147/dddt.S244099